Johnson & Johnson has warned against giving its vaccine to people who have ever developed capillary leak syndrome. A few cases were even fatal.
People who have developed the extremely rare capillary leak syndrome in the past should not receive a corona vaccine from Johnson & Johnson.
This emerges from the manufacturer’s so-called Rote-Hand-Brief, which was distributed by the Paul Ehrlich Institute (PEI). Accordingly, during the first few days after the administration of this vaccine, cases of capillary leak syndrome were ‘very rarely reported, in some cases fatal’.
Thus, the vaccine is contraindicated in people who have developed capillary leak syndrome in the past, it said. Capillary leak syndrome is an extremely rare but potentially life-threatening disease. According to the information, it is characterized, among other things, by acute episodes of edema (water retention) mainly in the extremities and low blood pressure. Immediate treatment is necessary if symptoms occur after vaccination with Johnson & Johnson.
According to the vaccination information sheet, people who have ever had capillary leak syndrome should also not be vaccinated with AstraZeneca’s product (Vaxzevria). There it says about the ‘very rare’ cases that have occurred: ‘The capillary leak syndrome appeared in the first days after vaccination and is characterized by rapidly progressive swelling of the arms and legs, sudden weight gain and a feeling of weakness.’ Immediate medical treatment is required.